Who is sponsoring NCT05000736?

NCT05000736 is sponsored by Chinese Academy of Medical Sciences.

What drugs are being tested in NCT05000736?

Interventions in NCT05000736: palbociclib + aromatase inhibitor, fulvestrant.

What condition does NCT05000736 study?

NCT05000736 studies Hormone Receptor Positive Advanced Breast Cancer.

Is NCT05000736 still recruiting?

NCT05000736 is currently status unknown. Last updated 29 April 2022.

Last reviewed 2022-04-29 · How we verify

NCT05000736: CAPACITY

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparative Effectiveness of Palbociclib Plus AI Versus Fulvestrant for HR+/HER2- ABC

Status unknown Last updated 29 April 2022

What this trial tests

trial testing palbociclib + aromatase inhibitor in Hormone Receptor Positive Advanced Breast Cancer in 600 participants. Status unknown.

Timeline

1 September 2021

Primary endpoint
1 September 2022

1 September 2022

Quick facts

Lead sponsor	Chinese Academy of Medical Sciences
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	600
Start date	1 September 2021
Primary completion	1 September 2022
Estimated completion	1 September 2022
Sites	1 location across China

Drugs / interventions tested

palbociclib + aromatase inhibitor (palbociclib-aromatase-inhibitor) — full drug profile →
fulvestrant (fulvestrant) — full drug profile →

Conditions studied

Hormone Receptor Positive Advanced Breast Cancer — all drugs for Hormone Receptor Positive Advanced Breast Cancer →

Sponsor

Chinese Academy of Medical Sciences — full company profile →

Who can join

18 and older, female only, with Hormone Receptor Positive Advanced Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A retrospective cohort study conducted at the Cancer Hospital Chinese Academy of Medical Sciences to compare the effectiveness of palbociclib plus AI therapy and fulvestrant monotherapy as initial endocrine therapy in the patients with HR+/HER2- advanced breast cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Chinese Academy of Medical Sciences trials

Trials by the same sponsor.

NCT05522894 — AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC · Phase 2 · unknown
NCT05499715 — A Phase I Clinical Study to Evaluate the Safety, the Tolerability, the Pharmacokinetic Characteristics and the Efficacy · Phase 1 · unknown
NCT05484024 — Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer · Phase 2, PHASE3 · not yet recruiting
NCT05543070 — Low-dose Radiotherapy in iNHL · Phase 2 · unknown
NCT05460403 — Adjuvant Radiotherapy for Patients With Esophageal Squamous Cell Carcinoma After R0 Resection · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05000736 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese Academy of Medical Sciences
Last refreshed: 29 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05000736.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing